Martin Whitaker purchased a total of 19,146 Ordinary Shares at 29.3 pence per share, to be held in pension schemes for the beneficial interest of his dependent children.. Founded in 2004, Diurnal is a UK- headquartered, European-based specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic...

Diurnal Group 30.5p £37.1m (DNL.L) Diurnal, announces that the Marketing Authorisation Application (MAA) for Chronocort® (modifie d release hydrocortisone) as a treatment for the rare condition congenital adrenal hyperplasia (CAH) in Europe has passed validation with the European Medicines Agency.The EMA validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. CAH is an orphan genetic condition caused by a block in cortisol production, an essential adrenal steroid hormone required for healthy life. A lack of cortisol in turn causes the over- production of male steroid hormones (androgens). Cortisol deficiency and over-production of androgens can lead to increased mortality, infertility and issues during sexual development, including ambiguous genitalia, precocious puberty and short stature. Sufferers, even if treated, remain at risk of death through an adrenal crisis. The condition is estimated to affect a total of approximately 41k adult patients in Europe, with over 400k in the rest of the world. #DNL

Diurnal #DNL : Marketing Authorisation Application validation Share price: 30.5p; Market Capitalisation: £37.1m Diurnal, the developer of therapies for rare hormonal diseases, provided an update regarding its Marketing Authorisation Application (MAA) for Chronocort® which has been submitted to the EMA, the European regulator. The Chronocort® MAA has been validated by the EMA which are now beginning the formal review process. Chronocort® is a potential candidate for the treatment of patients with congenital adrenal hyperplasia (CAH), a rare condition thought to affect 41,000 adult patients in Europe. The validation of the MAA is a positive step toward achieving regulatory approval for Chronocort®, for which an approval decision is expected in Q121 with a recent placing providing sufficient capital to commercialise Chronocort®. If approved, this would be the second product to be approved by the EMA, the first being Alkindi®, a hormone replacement therapy for adrenal insufficiency, an orphan disease. In H120, Alkindi posted revenues of £1.1m (H119: £0.2m). *One of the authoring analysts has an interest in Diurnal shares

Diurnal Group Plc #DNL announced that the Marketing Authorisation Application (MAA) for Chronocort (modified release hydrocortisone) as a treatment for the rare condition congenital adrenal hyperplasia (CAH) in Europe has passed validation with the European Medicines Agency (EMA), which confirms that the submission is sufficiently complete to begin the formal review process.

RNS Number: 3047 I Diurnal Group PLC 01 April 2020 01 April 2020. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that the Marketing Authorisation Application for Chronocort ® as a treatment for the rare condition congenital adrenal hyperplasia in Europe has passed validation with...

RNS Number: 1249 I Diurnal Group PLC 30 March 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

End of Announcement- EQS News Service.

RNS Number: 9439 H Diurnal Group PLC 27 March 2020 DTR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

Diurnal (DNL.L): US licencing agreement Share price: 30.1p; Market Capitalisation: £26.5m · Diurnal, the developer of therapies for rare hormonal diseases, struck a US licencing agreement with Eton Pharmaceuticals (ETON.NQ) regarding its Alkindi® treatment. · As part of the exclusive agreement, Diurnal will receive an upfront payment totalling $5m, of which $3.5m is in cash and the remainder in Eton shares. · Diurnal is responsible for obtaining US registration for Alkindi® Sprinkle with Eton responsible for commercialisation activities, such as pricing and reimbursement. · The Group is eligible for a further $2.5m cash milestone payment upon initial US sales, double-digit royalty payments and sales-based milestone payments of up to $45m. · Alkindi® Sprinkle is a hormone replacement therapy for adrenal insufficiency, an orphan disease, in patients under 17 years old. Earlier this year, Diurnal had its New Drug Application (NDA) for Alkindi® Sprinkle accepted by the US FDA earlier this year and expects an approval decision and grant of Orphan Drug Status in Q420. Alkindi® has already been approved in Europe and posted H1-20 revenues of £1.1m (H1-19: £0.2m).A recent £11.2m placing has provided the Group with capital to commercialise its second asset, Chronocort® for the treatment for adult and adolescent patients with the rare condition congenital adrenal hyperplasia (CAH), larger addressable patient population than adrenal insufficiency. In December the Group submitted a Market Authorisation Application (MAA) to the EMA, the European regulator, for Chronocort® with a decision expected in Q121. *One of the authoring analysts has an interest in Diurnal shares #DNL

Diurnal Group 35.5p £36m #DNL The specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has entered into an exclusive licence agreement for its product, Alkindi® Sprinkle (hydrocortisone granules in capsules for opening), in the United States with the specialty pharmaceutical company, Eton Pharmaceuticals, Inc. (NASDAQ: ETON "Eton"). Under the terms of the licence agreement, Diurnal will receive a non-refundable upfront payment of $5.0m, of which $3.5m is in cash and $1.5m is through the issue to Diurnal of 379,474 new Eton shares, and will receive an additional $2.5m cash milestone payment upon first commercial sale in the US following regulatory approval and grant of Orphan Drug Status (currently anticipated in Q4 2020). Diurnal will receive a tiered royalty on sales ranging from low double-digits to high teens and is also due tiered sales-based milestone payments of up to $45m in aggregate subject to annual sales thresholds. Eton is a NASDAQ-listed specialty pharmaceutical company focused on developing, acquiring and commercialising innovative products. Eton is primarily focused on hospital and paediatric products, including those in endocrinology. Eton's first commercial product, Biorphen®, (phenylephrine hydrochloride) is the only FDA approved ready-to-use formulation of phenylephrine injection and was launched in December 2019.

Richard Bungay, Chief Financial Officer, purchased 10,782 Ordinary Shares at a price of 37.45 pence per Ordinary Share.. Founded in 2004, Diurnal is a UK- headquartered, European specialty pharma company developing pharmaceutical products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal...

Total up-front payment and future milestones of up to $52.5 million. Diurnal Group plc, the specialty pharmaceutical company targeting patient needs in chronic endocrine diseases, announces that it has entered into an exclusive licence agreement for its product, Alkindi ® Sprinkle, in the United States with the specialty pharmaceutical company, Eton...

RNS Number: 7510 H Diurnal Group PLC 26 March 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 7501 H Diurnal Group PLC 26 March 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 5960 H Diurnal Group PLC 25 March 2020 NEITHER THIS ANNOUNCEMENT NOR ANY PART OF IT CONSTITUTES AN OFFER TO SELL OR ISSUE OR THE SOLICITATION OF AN OFFER TO BUY, SUBSCRIBE FOR OR ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL AND THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION OR...

RNS Number: 0978 H Diurnal Group PLC 20 March 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 0811 H Diurnal Group PLC 20 March 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.